NEW YORK (GenomeWeb News) – Gene Logic today said it will try to discover new development paths for drug candidates discontinued in clinical trials by Eli Lilly.
 
The candidates were discontinued for reasons other than safety, Gene Logic said.
 
Under the deal, Gene Logic has the option to receive an exclusive license to any drug candidate Eli Lilly decides not to purse. Eli Lilly would receive success-based milestone and royalty payments on those candidates.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.